These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

342 related articles for article (PubMed ID: 23954889)

  • 1. Pomalidomide, cyclophosphamide, and prednisone for relapsed/refractory multiple myeloma: a multicenter phase 1/2 open-label study.
    Larocca A; Montefusco V; Bringhen S; Rossi D; Crippa C; Mina R; Galli M; Marcatti M; La Verde G; Giuliani N; Magarotto V; Guglielmelli T; Rota-Scalabrini D; Omedé P; Santagostino A; Baldi I; Carella AM; Boccadoro M; Corradini P; Palumbo A
    Blood; 2013 Oct; 122(16):2799-806. PubMed ID: 23954889
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial.
    Richardson PG; Oriol A; Beksac M; Liberati AM; Galli M; Schjesvold F; Lindsay J; Weisel K; White D; Facon T; San Miguel J; Sunami K; O'Gorman P; Sonneveld P; Robak P; Semochkin S; Schey S; Yu X; Doerr T; Bensmaine A; Biyukov T; Peluso T; Zaki M; Anderson K; Dimopoulos M;
    Lancet Oncol; 2019 Jun; 20(6):781-794. PubMed ID: 31097405
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase 1/2 study of lenalidomide combined with low-dose cyclophosphamide and prednisone in lenalidomide-refractory multiple myeloma.
    Nijhof IS; Franssen LE; Levin MD; Bos GMJ; Broijl A; Klein SK; Koene HR; Bloem AC; Beeker A; Faber LM; van der Spek E; Ypma PF; Raymakers R; van Spronsen DJ; Westerweel PE; Oostvogels R; van Velzen J; van Kessel B; Mutis T; Sonneveld P; Zweegman S; Lokhorst HM; van de Donk NWCJ
    Blood; 2016 Nov; 128(19):2297-2306. PubMed ID: 27647864
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I-II trial of oral cyclophosphamide, prednisone and lenalidomide for the treatment of patients with relapsed and refractory multiple myeloma.
    Reece DE; Masih-Khan E; Atenafu EG; Jimenez-Zepeda VH; Anglin P; Chen C; Kukreti V; Mikhael JR; Trudel S
    Br J Haematol; 2015 Jan; 168(1):46-54. PubMed ID: 25146584
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lenalidomide, melphalan, prednisone and thalidomide (RMPT) for relapsed/refractory multiple myeloma.
    Palumbo A; Larocca A; Falco P; Sanpaolo G; Falcone AP; Federico V; Canepa L; Crugnola M; Genuardi M; Magarotto V; Petrucci MT; Boccadoro M
    Leukemia; 2010 May; 24(5):1037-42. PubMed ID: 20376079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.
    Gay F; Oliva S; Petrucci MT; Conticello C; Catalano L; Corradini P; Siniscalchi A; Magarotto V; Pour L; Carella A; Malfitano A; Petrò D; Evangelista A; Spada S; Pescosta N; Omedè P; Campbell P; Liberati AM; Offidani M; Ria R; Pulini S; Patriarca F; Hajek R; Spencer A; Boccadoro M; Palumbo A
    Lancet Oncol; 2015 Dec; 16(16):1617-29. PubMed ID: 26596670
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pembrolizumab plus pomalidomide and dexamethasone for patients with relapsed or refractory multiple myeloma (KEYNOTE-183): a randomised, open-label, phase 3 trial.
    Mateos MV; Blacklock H; Schjesvold F; Oriol A; Simpson D; George A; Goldschmidt H; Larocca A; Chanan-Khan A; Sherbenou D; Avivi I; Benyamini N; Iida S; Matsumoto M; Suzuki K; Ribrag V; Usmani SZ; Jagannath S; Ocio EM; Rodriguez-Otero P; San Miguel J; Kher U; Farooqui M; Liao J; Marinello P; Lonial S;
    Lancet Haematol; 2019 Sep; 6(9):e459-e469. PubMed ID: 31327687
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pomalidomide, cyclophosphamide, and dexamethasone for elderly patients with relapsed and refractory multiple myeloma: A study of the Korean Multiple Myeloma Working Party (KMMWP-164 study).
    Lee HS; Kim K; Kim SJ; Lee JJ; Kim I; Kim JS; Eom HS; Yoon DH; Suh C; Shin HJ; Mun YC; Kim MK; Lim SN; Choi CW; Kang HJ; Yoon SS; Min CK;
    Am J Hematol; 2020 Apr; 95(4):413-421. PubMed ID: 31919872
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pomalidomide alone or in combination with dexamethasone in Japanese patients with refractory or relapsed and refractory multiple myeloma.
    Matsue K; Iwasaki H; Chou T; Tobinai K; Sunami K; Ogawa Y; Kurihara M; Midorikawa S; Zaki M; Doerr T; Iida S
    Cancer Sci; 2015 Nov; 106(11):1561-7. PubMed ID: 26292221
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase 1b study of isatuximab plus pomalidomide/dexamethasone in relapsed/refractory multiple myeloma.
    Mikhael J; Richardson P; Usmani SZ; Raje N; Bensinger W; Karanes C; Campana F; Kanagavel D; Dubin F; Liu Q; Semiond D; Anderson K
    Blood; 2019 Jul; 134(2):123-133. PubMed ID: 30862646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.
    Suvannasankha A; Fausel C; Juliar BE; Yiannoutsos CT; Fisher WB; Ansari RH; Wood LL; Smith GG; Cripe LD; Abonour R
    Oncologist; 2007 Jan; 12(1):99-106. PubMed ID: 17227904
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Carfilzomib, pomalidomide, and dexamethasone for relapsed or refractory myeloma.
    Shah JJ; Stadtmauer EA; Abonour R; Cohen AD; Bensinger WI; Gasparetto C; Kaufman JL; Lentzsch S; Vogl DT; Gomes CL; Pascucci N; Smith DD; Orlowski RZ; Durie BG
    Blood; 2015 Nov; 126(20):2284-90. PubMed ID: 26384354
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma.
    Baz RC; Martin TG; Lin HY; Zhao X; Shain KH; Cho HJ; Wolf JL; Mahindra A; Chari A; Sullivan DM; Nardelli LA; Lau K; Alsina M; Jagannath S
    Blood; 2016 May; 127(21):2561-8. PubMed ID: 26932802
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pomalidomide, cyclophosphamide, and dexamethasone for relapsed multiple myeloma.
    Garderet L; Kuhnowski F; Berge B; Roussel M; Escoffre-Barbe M; Lafon I; Facon T; Leleu X; Karlin L; Perrot A; Moreau P; Marit G; Stoppa AM; Royer B; Chaleteix C; Tiab M; Araujo C; Lenain P; Macro M; Voog E; Benboubker L; Allangba O; Jourdan E; Orsini-Piocelle F; Brechignac S; Eveillard JR; Belhadj K; Wetterwald M; Pegourie B; Jaccard A; Eisenmann JC; Glaisner S; Mohty M; Hulin C; Loiseau HA; Mathiot C; Attal M
    Blood; 2018 Dec; 132(24):2555-2563. PubMed ID: 30282798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase II study of melphalan, thalidomide and prednisone combined with oral panobinostat in patients with relapsed/refractory multiple myeloma.
    Offidani M; Polloni C; Cavallo F; Liberati AM; Ballanti S; Pulini S; Catarini M; Alesiani F; Corvatta L; Gentili S; Caraffa P; Boccadoro M; Leoni P; Palumbo A
    Leuk Lymphoma; 2012 Sep; 53(9):1722-7. PubMed ID: 22335534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pomalidomide and dexamethasone combination with additional cyclophosphamide in relapsed/refractory multiple myeloma (AMN001)-a trial by the Asian Myeloma Network.
    Soekojo CY; Kim K; Huang SY; Chim CS; Takezako N; Asaoku H; Kimura H; Kosugi H; Sakamoto J; Gopalakrishnan SK; Nagarajan C; Wei Y; Moorakonda R; Lee SL; Lee JJ; Yoon SS; Kim JS; Min CK; Lee JH; Durie B; Chng WJ
    Blood Cancer J; 2019 Oct; 9(10):83. PubMed ID: 31594919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The addition of cyclophosphamide to lenalidomide and dexamethasone in multiply relapsed/refractory myeloma patients; a phase I/II study.
    Schey SA; Morgan GJ; Ramasamy K; Hazel B; Ladon D; Corderoy S; Jenner M; Phekoo K; Boyd K; Davies FE
    Br J Haematol; 2010 Aug; 150(3):326-33. PubMed ID: 20553268
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Melflufen plus dexamethasone in relapsed and refractory multiple myeloma (O-12-M1): a multicentre, international, open-label, phase 1-2 study.
    Richardson PG; Bringhen S; Voorhees P; Plesner T; Mellqvist UH; Reeves B; Paba-Prada C; Zubair H; Byrne C; Chauhan D; Anderson K; Nordström E; Harmenberg J; Palumbo A; Sonneveld P
    Lancet Haematol; 2020 May; 7(5):e395-e407. PubMed ID: 32213344
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Melphalan, prednisone, thalidomide and defibrotide in relapsed/refractory multiple myeloma: results of a multicenter phase I/II trial.
    Palumbo A; Larocca A; Genuardi M; Kotwica K; Gay F; Rossi D; Benevolo G; Magarotto V; Cavallo F; Bringhen S; Rus C; Masini L; Iacobelli M; Gaidano G; Mitsiades C; Anderson K; Boccadoro M; Richardson P;
    Haematologica; 2010 Jul; 95(7):1144-9. PubMed ID: 20053869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.